Drug Trial Radar · NCT06361537
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
124
Planned (sponsor's estimate)
Start
Apr 30, 2024
Primary completion
Dec 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- OctapharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks
Conditions
- Acute Hereditary Angio Edema
Interventions
OCTA-C1-INHDrug
OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)
PlaceboOther
0.1 mL/kg BW 0.9% sodium chloride injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time (h) to beginning of unequivocal symptom relief at the defining site in blinded participants.Time frame: Within 4 hours after injection
Locations
29 sites in 14 countries. Site status is shown where the registry gives one.
Octapharma Research Site
Centennial, Colorado · Withdrawn
Octapharma Research Site
Farmington Hills, Michigan · Withdrawn
Octapharma Research Site
Toledo, Ohio · Withdrawn
Octapharma Research Site
Tirana, Albania · Withdrawn
Octapharma Research Site
Rosario, Argentina · Recruiting
Octapharma Research Site
Yerevan, Armenia · Recruiting
Octapharma Research Site
Sofia, Bulgaria · Recruiting
Octapharma Research Site
Bangalore, India · Not yet recruiting
Octapharma Research Site, Chhatrapati Sambhajinagar
Chhatrapati Sambhajinagar, India · Not yet recruiting
Octapharma Research Site
Hyderabad, India · Not yet recruiting
Octapharma Research Site
Patna, India · Not yet recruiting
Octapharma Research Site
Srinagar, India · Not yet recruiting
Octapharma Research Site
Pune, Maharashtra, India · Not yet recruiting
Octapharma Research Site
Almaty, Kazakhstan · Not yet recruiting
Octapharma Research Site
Almaty, Kazakhstan · Not yet recruiting
Octapharma Research Site
México, Mexico · Not yet recruiting
Octapharma Research Site
Mexico City, Mexico · Not yet recruiting
Octapharma Research Site
Podgorica, Montenegro · Withdrawn
Octapharma Research Site 5102
Lima, Peru · Recruiting
Octapharma Research Site 5103
Lima, Peru · Recruiting
Octapharma Research Site
Cluj-Napoca, Romania · Withdrawn
Octapharma Research Site
Kragujevac, Serbia · Withdrawn
Octapharma Research Site
Ankara, Turkey (Türkiye) · Not yet recruiting
Octapharma Research Site
Istanbul, Turkey (Türkiye) · Not yet recruiting
Octapharma Research Site
Izmir, Turkey (Türkiye) · Withdrawn
Octapharma Research Site
Sakarya, Turkey (Türkiye) · Not yet recruiting
Octapharma Research Site
Kyiv, Ukraine · Recruiting
Octapharma Research Site
Lviv, Ukraine · Withdrawn
Octapharma Research Site
Lviv, Ukraine · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.